Alzheimer’s disease (AD) refers to a decline in memory caused by characteristic brain changes asociated with aging. Between the ages of 65 and 85, the rate of AD doubles every 5 years, so that by age 85, approximately 35% of people suffer from AD.
The World Health Organization reports that approximately 37 million people worldwide suffer from dementia. Growth in sales of AD treatments is expected to triple from $ 4.3 billion in 2009 to $ 13.3 billion in 2019.
Although there are scientific leads in terms of understanding the disease progress in AD, there is no treatment that slows its progress. Five drugs have been approved for use in AD, but they show only transient beneficial effects in half of those to whom they are prescribed.
Clera’s new approach is to search for drugs that interfere with the critical chain of steps involved in laying beta-amyloid plaques. Clera is identifying a compound that will slow this process and thus prevent memory decline.